Turn Therapeutics Inc. Announces Private Common Stock Sale for $1.35M

What Happened
Turn Therapeutics Inc. announced in an 8‑K (filed Aug 17, 2026) that on August 14, 2026 it entered into securities purchase agreements with certain accredited existing series and seed investors to sell 135,000 shares of its common stock at $10.00 per share, generating aggregate gross proceeds of $1.35 million. The sale was a private placement conducted under Section 4(a)(2) of the Securities Act and Regulation D. The company also granted the investors certain registration rights for the shares.

Key Details

• Date of agreements: August 14, 2026; 8‑K filed August 17, 2026.
• Shares sold: 135,000 shares of common stock.
• Price and proceeds: $10.00 per share; $1.35 million aggregate gross proceeds.
• Placement type: Private placement with accredited existing series and seed investors; exemption relied on Section 4(a)(2) and Regulation D.
• Additional term: Investors were granted registration rights for the shares.

Why It Matters
This transaction provides Turn Therapeutics with immediate additional capital ($1.35M) from existing accredited investors, which can support near‑term corporate needs without a public offering. Because the sale was a private placement with registration rights, the company preserved flexibility in raising funds while giving investors a route to register and eventually sell shares in the public market.